- BioCina has appointed Dr. Thomas Broudy as its new Chief Executive Officer to oversee the company’s next phase of growth.
- The appointment follows the merger of BioCina’s Adelaide and Perth sites, creating an integrated offering for biologic drug substance and sterile drug product manufacturing.
BioCina, a global pharmaceutical contract development and manufacturing organisation (CDMO), has appointed Dr. Thomas Broudy as Chief Executive Officer to lead its biologic drug substance and sterile drug product development and manufacturing operations.
Dr. Broudy brings over two decades of experience in the biopharmaceutical and CDMO industries, including roles spanning operations, business development, and strategic leadership. Before this appointment, he served as Chairman of BioCina’s Board of Directors and Operating Partner at Bridgewest Group, which owns BioCina.
“BioCina is entering an exciting new chapter,” said Dr. Masood Tayebi, Co-Founder and CEO of Bridgewest Group. “Tommy’s deep understanding of our business, his global industry experience, and his proven track record of leadership make him the right person to guide BioCina’s continued growth and innovation.”
Dr. Broudy has held senior roles across the drug development value chain, including at BioDuro-Sundia, where he led corporate development and marketing for the 2,500-person integrated CRDMO. His experience also includes leadership at Molecular Response, January Therapeutics, and Crown Bioscience.
The leadership change follows BioCina’s merger of its Adelaide-based drug substance facility—focused on microbial protein, plasmid, and mRNA/LNP production—and its Perth sterile drug product facility, which handles ampoules, vials, cartridges, and prefilled syringes. The integration enables BioCina to offer clients a fully unified service model from clinical to commercial stages.
